The key details to know:
1. The pharmacy chain agreed to pay more than $269 million to resolve allegations it improperly billed Medicare and Medicaid for hundreds of thousands of insulin pens beneficiaries didn’t need. Walgreens falsely stated that what was dispensed didn’t exceed a patient’s daily prescription, according to prosecutors. The company’s electronic management system also prevented pharmacists from dispensing partial insulin pens, even when the patient didn’t require a larger dose, prosecutors said.
2. In a separate action brought against the company, Walgreens agreed to pay $60 million. Prosecutors alleged that Walgreens overcharged federal healthcare programs for medications dispensed through its Prescription Savings Program.
3. The state of New York will receive $14.5 million as part of the settlement. In a statement to the New York Law Journal, Walgreens said it admitted no wrongdoing and fully cooperated with the government.
More articles on coding, billing and collections:
Group Insurance Commission lowers copays to drive patients to ASCs: 3 details
3 ways to ensure coding & billing accuracy at your ASC
5 key ASC price transparency do’s and don’ts to know
